PRODUCT PORTFOLIO

Essential Medicines, Delivered with Precision

C AT E G O RY 1

Human Blood Plasma Derivatives

Manufactured under strict plasma-derived biologics standards and distributed with unbroken cold-chain integrity.

AlbuCore
Human Albumin for Injection · 5g / 10g / 20g per 100ml ·
IV Use Only
GlobuCore
Human Normal Immunoglobulin for Injection · 5g / 10g /
20g per 100ml · IV Use Only

C AT E G O RY 2

Iohexol & Iopamidol Injection USP

Non-ionic, water-soluble contrast agents for CT imaging, angiography, and urography — distributed under strict quality controls to hospitals and diagnostic imaging centres across MENA and Africa.

HexoXam
Iohexol 300mg · 100ml vial
PamiXam
Iopamidol 370mg · 100ml vial

C AT E G O RY 2

Gadopentetate Dimeglumine Injection

Gadolinium-based contrast agent for intravenous use in diagnostic MRI in adults and children (2 years and older) to facilitate visualization of lesions and abnormal vascularity in the central nervous system: brain, spine and associated tissues.

GadoXam
Gadolinium (Gadopentetate Dimeglumine) 469mg/ml ·
20ml vial

PRODUCT PIPELINE

Under Development

ALL PRODUCTS LISTED ARE CURRENTLY UNDER DEVELOPMENT – NOT YET REGISTERED OR LICENSED

ITC Pharma is currently building a dedicated portfolio focused on the sourcing, distribution, and delivery of high-quality biological medicines, specifically monoclonal antibodies (mAb), to healthcare providers. Our pipeline targets the treatment of serious and life-threatening conditions, including oncology, autoimmune disorders, and chronic inflammatory diseases, where access to advanced biologic therapies remains critically limited. We collaborate exclusively with internationally recognised manufacturers to ensure full regulatory compliance, cold-chain integrity, and consistent product quality. By bridging the gap between global biopharmaceutical innovation and underserved markets, ITC Pharma aims to improve patient outcomes and expand access to cutting-edge treatments. We remain committed to the highest standards of safety, efficacy, and transparency as we advance these therapies toward availability.